全文获取类型
收费全文 | 11844篇 |
免费 | 1041篇 |
国内免费 | 308篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 260篇 |
妇产科学 | 91篇 |
基础医学 | 4052篇 |
口腔科学 | 281篇 |
临床医学 | 680篇 |
内科学 | 2128篇 |
皮肤病学 | 208篇 |
神经病学 | 271篇 |
特种医学 | 156篇 |
外国民族医学 | 1篇 |
外科学 | 523篇 |
综合类 | 1370篇 |
预防医学 | 1151篇 |
眼科学 | 73篇 |
药学 | 665篇 |
2篇 | |
中国医学 | 543篇 |
肿瘤学 | 674篇 |
出版年
2023年 | 259篇 |
2022年 | 258篇 |
2021年 | 522篇 |
2020年 | 432篇 |
2019年 | 362篇 |
2018年 | 381篇 |
2017年 | 418篇 |
2016年 | 445篇 |
2015年 | 486篇 |
2014年 | 691篇 |
2013年 | 877篇 |
2012年 | 626篇 |
2011年 | 703篇 |
2010年 | 583篇 |
2009年 | 614篇 |
2008年 | 534篇 |
2007年 | 580篇 |
2006年 | 507篇 |
2005年 | 450篇 |
2004年 | 452篇 |
2003年 | 341篇 |
2002年 | 305篇 |
2001年 | 290篇 |
2000年 | 207篇 |
1999年 | 201篇 |
1998年 | 157篇 |
1997年 | 145篇 |
1996年 | 115篇 |
1995年 | 116篇 |
1994年 | 125篇 |
1993年 | 105篇 |
1992年 | 88篇 |
1991年 | 81篇 |
1990年 | 69篇 |
1989年 | 77篇 |
1988年 | 69篇 |
1987年 | 56篇 |
1986年 | 52篇 |
1985年 | 66篇 |
1984年 | 53篇 |
1983年 | 33篇 |
1982年 | 56篇 |
1981年 | 38篇 |
1980年 | 44篇 |
1979年 | 34篇 |
1978年 | 21篇 |
1977年 | 19篇 |
1976年 | 27篇 |
1975年 | 6篇 |
1974年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
2.
Specialized pro-resolving mediators (SPMs) are endogenous small molecules produced mainly from dietary omega-3 polyunsaturated fatty acids by both structural cells and cells of the active and innate immune systems. Specialized pro-resolving mediators have been shown to both limit acute inflammation and promote resolution and return to homeostasis following infection or injury. There is growing evidence that chronic immune disorders are characterized by deficiencies in resolution and SPMs have significant potential as novel therapeutics to prevent and treat chronic inflammation and immune system disorders. This review focuses on important breakthroughs in understanding how SPMs are produced by, and act on, cells of the adaptive immune system, specifically macrophages, B cells and T cells. We also highlight recent evidence demonstrating the potential of SPMs as novel therapeutic agents in topics including immunization, autoimmune disease and transplantation. 相似文献
3.
4.
5.
6.
Danka Cholujova Gabor Beke Zachary R. Hunter Teru Hideshima Ludmila Flores Tatiana Zeleznikova Denisa Harrachova Lubos Klucar Merav Leiba Lubos Drgona Steven P. Treon Efstathios Kastritis David M. Dorfman Kenneth C. Anderson Jana Jakubikova 《International journal of cancer. Journal international du cancer》2023,152(9):1947-1963
Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by malignant lymphoplasmacytic cells in the bone marrow (BM). To dissect the pathophysiology of WM, we evaluated clonal cells by mapping of B cell lymphomagenesis with adaptive and innate immune tumor microenvironment (TME) in the BM of WM patients using mass cytometry (CyTOF). In-depth immunophenotypic profiling of WM cells exhibited profound expansion of clonal cells in both unswitched and switched memory B cells and also plasma cells with aberrant expression variations. WM B lymphomagenesis was associated with reduction of most B cell precursors assessed with the same clonally restricted light chain and phenotypic changes. The immune TME was infiltrated by mature monocytes, neutrophils and adaptive T cells, preferentially subsets of effector T helper, effector CTL and effector memory CTL cells that were associated with superior overall survival (OS), in contrast to progenitors of T cells and myeloid/monocytic lineage subsets that were suppressed in WM cohort. Moreover, decrease in immature B and NKT cells was related to worse OS in WM patients. Innate and adaptive immune subsets of WM TME were modulated by immune checkpoints, including PD-1/PD-L1&PD-L2, TIGIT/PVR, CD137/CD137-L, CTLA-4, BTLA and KIR expression. The response of ibrutinib treatment to the reduction of clonal memory B cell was associated with high levels of immature B cells and effector memory CTL cells. Our study demonstrates that CyTOF technology is a powerful approach for characterizing the pathophysiology of WM at various stages, predicting patient risk and monitoring the effectiveness of treatment strategies. 相似文献
7.
学者们对动脉血管的研究常聚焦在血管内膜动脉粥样硬化(As)斑块的形成,而很少关注血管外膜的免疫反应及其对疾病病程的影响。前期研究发现,老龄的ApoE-/-小鼠动脉外膜出现免疫细胞的有序集聚,形成类似淋巴结的异位淋巴组织,称之为动脉三级淋巴组织(ATLO),其形成对内膜As具有明显的调控作用。ATLO的发现及研究为As的研究指明了新的方向,并为其他疾病状况下三级淋巴组织(TLO)的研究提供了很好的范例。因此,阐明TLO的特点及形成机制对As的防治具有重要的意义,并为其在其他疾病中的临床运用提供坚实的基础。 相似文献
8.
9.